Logo 1200x628.jpg
CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement
01 août 2024 07h00 HE | CytoSorbents
CytoSorbents regains compliance with Nasdaq minimum bid price requirement
Logo 1200x628.jpg
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
30 juil. 2024 02h00 HE | CytoSorbents
CytoSorbents new modern website launch unifies corporate and product websites and highlights "Working to Save Lives Together"
Logo 1200x628.jpg
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
29 juil. 2024 08h00 HE | CytoSorbents
CytoSorbents new modern website launch unifies corporate and product websites and highlights "Working to Save Lives Together"
Logo 1200x628.jpg
CytoSorbents Secures $20 Million Credit Facility
02 juil. 2024 07h00 HE | CytoSorbents
$20 million credit facility provides CytoSorbents with important non-dilutive capital to support its regulatory and commercialization objectives
Logo 400x400.jpg
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
28 déc. 2023 07h00 HE | CytoSorbents
CytoSorbents Provides Update on STAR-T Trial and Final Independent DSMB Recommendation
Logo 400x400.jpg
CytoSorbents to Present at the 8th Annual Dawson James Conference
05 oct. 2023 07h00 HE | CytoSorbents
CytoSorbents to Highlight Company Progress at Dawson James Small Cap Investor Growth Conference
Logo 400x400.jpg
CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry
27 sept. 2023 07h00 HE | CytoSorbents
CytoSorbents summarizes real-world data from STAR Registry analysis being presented next week at European Association of Cardio-Thoracic Surgery Congress
Logo 400x400.jpg
CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
19 sept. 2023 07h00 HE | CytoSorbents
PRINCETON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat...
CytoSorbents New Logo - 2021.png
CytoSorbents’ Pivotal STAR-T Trial Reaches Second Key Milestone With 80 Patients Enrolled
20 avr. 2023 07h00 HE | CytoSorbents
PRINCETON, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...